Results 221 to 230 of about 175,700 (308)

MSC‐Derived Exosomal lnc‐AGT‐3: A Novel Anti‐Angiogenic Target in Age‐Related Macular Degeneration Through p53 Signaling Pathway

Aging Cell, Volume 25, Issue 2, February 2026.
MSC‐derived exosomes deliver lnc‐AGT‐3 to vascular endothelial cells, where it binds hnRNP K in the nucleus. This interaction inhibits p53 ubiquitination, enhancing p53 stabilization and transcriptional activation of anti‐angiogenic targets TSP1. Consequently, p53‐mediated signaling is potentiated, effectively suppressing choroidal neovascularization ...
Lingjie Kong, Xiaoyan Han, Siyi Qi, Duo Li, Jingyue Zhang, Linyu Zhang, Shujie Zhang, Qin Jiang, Biao Yan, Chen Zhao   +9 more
wiley   +1 more source

Neurobehavioral Changes in Macular Degeneration: Spatial Frequency Use in Scene Recognition. [PDF]

Invest Ophthalmol Vis Sci
Faurite C, Michaud C, Cousin E, Olivier P, Gallice M, Chiquet C, Pietras J, Attyé A, Soler V, Berry I, Mermillod M, Cottereau BR, Peyrin C.   +12 more
europepmc   +1 more source

Outsourced eye care in the Finnish capital region: Switching from fee‐for‐service to bundled payment model

Acta Ophthalmologica, Volume 104, Issue 1, Page 114-129, February 2026.
Abstract Purpose The demand for specialised eye care has quadrupled over the last two decades, driven by an aging population and the advent of new treatments. This surge has led to increased outsourcing by the Helsinki and Uusimaa Hospital District (HUS) Eye Hospital, initially relying on a fee‐for‐service model. This model, however, has been marked by
Susanna Moisander, Jukka Ari Olavi Moilanen, Hans Henrik Konstantin Backström, Olga Marjasova, Marko Juhani Myöhänen, Taina Pauliina Nykänen, Mikko Juhani Pietilä, Paulus Torkki   +7 more
wiley   +1 more source

Progression and topographic subtypes of Terrien marginal degeneration

Acta Ophthalmologica, Volume 104, Issue 1, Page 33-43, February 2026.
Abstract Purpose To report long‐term outcomes and to search for immunological and genetic risk factors in Terrien marginal degeneration (TMD). Methods Retrospective, in part prospective, hospital‐based longitudinal follow‐up study of 32 eyes of 16 Finnish patients from 2012 to 2023. Median follow‐up was 7.3 years (range, 0.3–15.2).
Minna Ruutila, Pauliina Repo, Annamari T. Immonen, Joni A. Turunen, Marja‐Liisa Lokki, A. Inkeri Lokki, Jukka Moilanen, Kari Krootila, Tero T. Kivelä   +8 more
wiley   +1 more source

Test–retest variability of the full‐field stimulus test in patients with retinitis pigmentosa: REPEAT Study Report No. 4

Acta Ophthalmologica, Volume 104, Issue 1, Page 89-97, February 2026.
Abstract Purpose To evaluate test–retest variability (TRV) of the full‐field stimulus test (FST) in patients with retinitis pigmentosa (RP) and poor best‐corrected visual acuity (BCVA; ≤20/50 Snellen; ≥0.40 logMAR), and to assess the reliability of FST as a clinical endpoint in future RP trials.
J. S. Karuntu, S. B. A. E. Tulp, C. J. F. Boon   +2 more
wiley   +1 more source

Treatment results switching from aflibercept to bevacizumab in wet age-related macular degeneration. [PDF]

Int J Ophthalmol
Kananen F.
europepmc   +1 more source

Intravitreal anti‐vascular endothelial growth factor injections and risks of stroke in patients with neovascular age‐related macular degeneration—A registry‐based cohort study

Acta Ophthalmologica, Volume 104, Issue 1, Page 98-105, February 2026.
Abstract Background Intravitreal Anti‐Vascular Endothelial Growth Factor (VEGF) rescues retinal vasculatures and prevents disease progression in patients with neovascular Age‐Related Macular Degeneration (nAMD). However, systemic anti‐VEGF may increase the risk of thromboembolic related complications including stroke and TIA. This study aims to explore
A. H. Falemban, K. Söderberg‐Löfdal, F. Jonsson, S. Almlöf‐Sarman, M. von Euler, I. Westborg   +5 more
wiley   +1 more source

Hydrogel-encapsulated antioxidant nanotherapeutics against age-related macular degeneration (AMD) oxidative damage. [PDF]

Int J Pharm X
Xu J, Cai T, Li J, Ge-Zhang S, Jiang Z, Cao M.   +5 more
europepmc   +1 more source

Continuity of care and risk of vision loss in patients with newly developed macular degeneration

Acta Ophthalmologica, Volume 104, Issue 1, Page e39-e47, February 2026.
Abstract Purpose Neovascular age‐related macular degeneration (AMD) is a major cause of vision loss. Effective treatment requires sustained care, which may be influenced by continuity of care (COC). Understanding this association is crucial for improving patient outcomes.
In Hwan Cho, Minah Park, Dae Joong Ma, In Hwan Hong, Hyunkyu Kim, Seung Hoon Kim   +5 more
wiley   +1 more source

Standardization of Imaging Criteria for Detecting Macular Fibrosis in Neovascular Age-Related Macular Degeneration. [PDF]

Ophthalmol Sci
Chakravarthy U, Csincsik L, Teo KYC, Munk MR, Grewal DS, Guymer RH, Jaffe GJ, Peto T, Sadda SR, Staurenghi G, Cheung CMG, International Retinal Imaging Society Research Group.   +11 more
europepmc   +1 more source